ShareSpot

  • Short Bites: Do I Pre-medicate Patients Based on a High Viral Load and Low CD4 Count?

    The question I most commonly get asked by oral health providers is...

    Do I pre-medicate patients based on a high viral load and low CD4 count?

    There is no supporting data to support the need for routine antibiotic coverage pre or post dental treatment based on the...

  • Xerostomia in Patients Living with HIV

    In the United States, it is estimated that 1.1 million people are living with HIV. Of those, 1 in 7 do not know they are infected.[1] The number of new HIV diagnoses fell 19% from 2005 to 2014.[1] Because HIV testing has remained stable or increased in recent years, this decrease in diagnoses...

  • Periodontal Health in the Era of Antiretroviral Therapy

    The U.S. Department of Health and Human Services currently recommends that every person living with HIV begin antiretroviral therapy (ART) as soon as possible after diagnosis. Increased availability of testing and treatment along with the above guidelines have reduced the number of new HIV...

  • One in Nine American Men are Infected with Oral HPV

    According to a new study published in the Journal Annals of Internal Medicine, one in nine American men is infected with the oral form of the human papillomavirus (HPV). Nationwide, rates of oral HPV infection are 11.5% of men vs. 3.2% women. HPV 16, the most common type of high-risk HPV and...

  • Giving New Life to New Jersey Syringe Access Programs

    I had the honor to help develop the first legal syringe access program (SAP) in Atlantic City, NJ, almost 10 years ago. In 2006, the New Jersey legislature passed the Blood-Borne Disease Harm Reduction Act, which allowed for the establishment of up to six pilot SAPs in NJ; however, approval from...

  • Doravirine in Initial Therapy: DRIVE-AHEAD Study

    Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (...

  • Bictegravir in Initial Therapy

    Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...

  • On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen

    The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an...

  • Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference

    Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair

    The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...

  • Evolving: A Journey in Practice Transformation

    I remember driving to Chicago on my first day as a Midwest AETC Practice Transformation (PT) Coach filled with both excitement and apprehension to participate in a 3-day intensive training titled Building Blocks of High Performing Primary Care. While the concepts of PT were familiar to me after...

  • CROI 2017: Dolutegravir in 2-Drug Simplification Studies

    In recent years, a number of studies have evaluated 2-drug or even 1-drug ARV regimens, either in initial therapy or in switch regimens for patients with virologic suppression on 3-drug therapy. In general, these have not been as successful in achieving or maintaining virologic suppression as...

  • CROI 2017: Failure of Dolutegravir Monotherapy

    Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...

  • CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment

    Doravirine is an investigational NNRTI that is active in vitro against many common NNRTI resistance mutations (including K103N, Y181C, and E138K). It is given once daily, has no food restrictions, and can be given with acid-blocking medications. In a Phase 2 study of treatment-...

  • CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison

     

    Bictegravir is an investigational integrase inhibitor that is dosed once daily, unboosted. It is active in vitro against many viruses with integrase resistance mutations. A Phase 2 double-blind placebo-controlled study randomized treatment-naive patients (n...

  • Tuesday Morning HIV Discussion Series: South Central AETC collaborates with the University of Texas Southwestern Medical Center

    In February 2016 Elyse Malanowski, MLS, became the Education Coordinator for Parkland Health and Hospital System/North Texas for the South Central AETC (SCAETC). The SCAETC along with the University of Texas Southwestern (UTSW) Medical Center co-host a weekly informational session for clinicians...

  • Journal Articles by AETC-Affiliated Researchers and Faculty--2016

    It's been a busy year for the AETC community, and we are proud to present the following compilation of published studies produced by members of our network during the 2016 calendar year.   Also included is the HRSA/HAB Workforce Survey results published in the AAHIVM HIV Specialist.  AETC-...

  • Join HAB and NQC in the end+disparities Learning Exchange

    The National Quality Center (NQC) and HIV/AIDS Bureau (HAB) are pleased to announce the end+disparities Learning Exchange! Please watch the informational video and share it with your colleagues and social media contacts!

    The 9-month initiative is open to all Ryan White HIV/AIDS Program (...

  • Addiction Recovery and HIV: Finding Synergy

    When we talk about HIV and drug addiction, we most often focus on injection drug use (IDU) as a risk factor for HIV transmission. While only 2.6% of the country’s population over the age of 13 reports having injected drugs at some point during their lives1, approximately 10% of new HIV...

  • HIV Meds Update: PrEP Uptake by Sex, Race, and Age

    At the ASM Microbe meeting in June, researchers from Gilead Sciences presented data on use of TDF/FTC (Truvada) PrEP in the United States according to sex and race. They evaluated national pharmacy databases to identify prescriptions of TDF/FTC given for PrEP between January 2012 and September...

  • HIV Meds Update - RAPID: Immediate ART Initiation

    This publication presents the results of San Francisco General Hospital's Ward 86 pilot study of immediate ART initiation. This RAPID program systematically offered ART to patients upon diagnosis of HIV; patients were referred from HIV testing sites in San Francisco. Of the 39 patients who...